Crossmark

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

Crossref DOI link: https://doi.org/10.1136/rmdopen-2022-002216

Published Online: 2022-06-03

Published Print: 2022-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Krieckaert, Charlotte https://orcid.org/0000-0001-6591-7838
Hernández-Breijo, Borja https://orcid.org/0000-0002-2630-3312
Gehin, Johanna Elin https://orcid.org/0000-0002-9896-0223
le Mélédo, Guillaume

Balsa, Alejandro https://orcid.org/0000-0001-8070-7062
Jani, Meghna https://orcid.org/0000-0002-1487-277X
Mulleman, Denis https://orcid.org/0000-0003-4089-7513
Navarro-Compan, Victoria

Wolbink, Gertjan

Isaacs, John D https://orcid.org/0000-0002-6103-7056
van Tubergen, Astrid https://orcid.org/0000-0001-8477-0683
Funding

Funding for this research was provided by:

EULAR
License Information

License valid from 2022-06-03